U.S., May 20 -- ClinicalTrials.gov registry received information related to the study (NCT07595900) titled 'Tocilizumab for the Treatment of Refractory Granulomatous Lobular Mastitis' on May 13.
Brief Summary: Non-Lactational Granulomatous Lobular Mastitis (NL-GLM) is an inflammatory disease of unknown etiology, characterized clinically by local breast masses, accompanied by redness and swelling of the overlying skin, sinus tract formation, and other symptoms. Currently, there is no universally accepted standard treatment for this condition; previous expert consensus or practice guidelines have mostly recommended systemic glucocorticoid therapy as the primary treatment approach. Our team's preliminary research has confirmed that local gluc...